Physician profile
Robert E Fowles
NPI 1811927965
$610,870.28
in general payments reported to CMS, 2019-2025
16 companies · $53K in 2025
The $53K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $14K · 2021: $55K · 2022: $144K · 2023: $182K · 2024: $91K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263K · Travel and Lodging: $49K · Food and Beverage: $8,534 · Consulting Fee: $4,800 · Education: $5.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $263,369.50 |
| Travel and Lodging | $48,775.33 |
| Food and Beverage | $8,533.76 |
| Consulting Fee | $4,800.00 |
| Education | $5.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $184,824.10 | 2019-2025 | Definity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147,238.10 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $93,592.86 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $87,088.20 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $78,472.41 | 2023-2024 | Verquvo |
| Pfizer INC. | $14,382.58 | 2019-2025 | |
| Boston Scientific Corporation | $4,162.18 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Amgen INC. | $365.51 | 2023-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $243.82 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $218.38 | 2022-2025 | |
| Amryt Pharma Holdings Ltd | $125.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $89.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.19 | 2021 | |
| Abbott Laboratories | $16.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.49 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.